p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma

p53 abnormalities are regarded as an independent prognostic marker in multiple myeloma. Patients harbouring this genetic anomaly are commonly resistant to standard therapy. Thus, various p53 reactivating agents have been developed in order to restore its tumour suppressive abilities. Small molecular...

Descripción completa

Detalles Bibliográficos
Autores principales: Teoh, P. J., Chng, W. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083709/
https://www.ncbi.nlm.nih.gov/pubmed/25028664
http://dx.doi.org/10.1155/2014/717919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083709/
https://www.ncbi.nlm.nih.gov/pubmed/25028664
http://dx.doi.org/10.1155/2014/717919

Ejemplares similares